Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).

David S. Miller,Virginia L. Filiaci,Robert S. Mannel,D.E. Cohn,Takashi Matsumoto,Krishnansu S. Tewari,Paul DiSilvestro,Michael L. Pearl,Peter A. Argenta,Matthew A. Powell,Susan Zweizig,David P. Warshal,Parviz Hanjani,Michael E. Carney,Helen Huang,David Cella,Richard J. Zaino,Gini F. Fleming

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).

2020

David S. Miller
Virginia L. Filiaci
Robert S. Mannel
D.E. Cohn
Takashi Matsumoto
Krishnansu S. Tewari
Paul DiSilvestro
Michael L. Pearl
Peter A. Argenta
Matthew A. Powell
Susan Zweizig
David P. Warshal
Parviz Hanjani
Michael E. Carney
Helen Huang
David Cella
Richard J. Zaino
Gini F. Fleming

PURPOSELimitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studie...

Keywords:

Endometrial cancer
Medicine
Internal medicine
MEDLINE
Oncology
Gynecologic oncology
Adverse effect
Regimen
Paclitaxel
Tolerability
Carboplatin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations